Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

By M. Clarke, J. Dick, P. Dirks, C. Eaves, Catriona H. M. Jamieson, D. L. Jones, Jane E. Visvader, Irving L. Weissman, G. Wahl. Cancer Research, 2006

3,082 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/174239fce203d970e5b799ae56b8531b8cd45fcc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Evolution of the cancer stem cell model. (2014, methodology): “For many cancers, CSCs represent a distinct population that can be prospectively isolated from the remainder of the tumor cells and can be shown to have clonal long-term repo-pulation and self-renewal capacity—the deﬁning features of a CSC (Clarke et al., 2006; Nguyen et al., 2012).”
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment (2009, background): “According to this model, tumor can be viewed as a result of abnormal organogenesis driven by CSCs, defined as self-renewing tumor cells able to initiate and maintain the tumor and to produce the heterogeneous lineages of cancer cells that compose the tumor (4, 5).”
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “The term 'cancer stem cell' does not imply that the cell is derived from a normal stem cel”
Exploring the role of cancer stem cells in radioresistance (2008, background): “jpg" NDATA ITEM> ]> A cancer stem cell is defined as a cell within a tumour that possesses the capacity to self-renew and to generate the heterogeneous lineages of cancer cells that comprise the tumou”
The epithelial-mesenchymal transition generates cells with properties of stem cells. (2008, neutral): “The findings presented here describe an unexpected convergence of two lines of recent research; stem cells have been documented in a variety of normal tissues, and more recently this paradigm was extended to neoplasias (Clarke et al., 2006; Reya et al., 2001).”
Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “Cancer stem cells, also known as tumor initiating cells, are cells that have the capacity to self-renew and to give rise to the heterogeneous lineages that are found within a tumor [35].”
The pan-ErbB negative regulator, Lrig1, is an intestinal stem cell marker that functions as a tumor suppressor (2012, neutral): “In the highly dynamic and rapidly renewing intestinal epithelium, it is thought that SCs, but not transit-amplifying and differentiated cells, have a sufficient lifespan to acquire the number of mutations required for cancer development (Clarke et al., 2006).”